# *Fiscal Year 2020 (FY20) Peer Reviewed Alzheimer's Research Program (PRARP) Reference Table of Award Mechanisms and Submission Requirements*

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| **Convergence Science Research Award:**<br>• Program Announcement<br>• General Application Instructions<br>**Grants.gov Funding Opportunity Number:**<br>W81XWH-20-PRARP-CSRA | **Level I:** Investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but **below** the level of Assistant Professor (or equivalent) at the time of the application submission deadline.<br>• Mentor required.<br>**Level II:** The Principal Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent). | **Intent:** To support innovative and impactful efforts to generate research resources, tools, and new avenues of investigation for researchers and/or practitioners in health sciences.<br>• **Level I**: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the Mentor(s). The Mentor(s) must possess qualifications, background, and experience in traumatic brain injury (TBI) and/or Alzheimer's disease (AD)/AD-related dementia (ADRD) research.<br>• **Level II** is intended to support PIs from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline.<br>**Applications must address one of the following FY20 PRARP Overarching Challenges:**<br>• Foundational Research<br>• Paucity of Clinical Studies<br>• Diagnostics and Prognostics<br>• Epidemiology<br>**Applications should address one of the following FY20 PRARP Focus Areas:**<br>• Mechanisms of Pathogenesis<br>• Biomarkers<br>• Epidemiology<br>• Novel Target Identification<br>• Bioinformatics<br>**Pharmacological interventions are specifically discouraged.** | **Level I:**<br>• Maximum funding of **$225,000** for direct costs (plus indirect costs).<br>• Maximum period of performance is **3** years.<br>**Level II:**<br>• Maximum funding of **$500,000** for direct costs (plus indirect costs).<br>• Maximum period of performance is **3** years.<br>**For Both Levels:**<br>Indirect costs may be proposed in accordance with the institution's rate agreement. | **Pre-Application (Letter of Intent):**<br>June 22, 2020, 5:00 p.m. Eastern time (ET)<br>**Application:**<br>July 21, 2020, 11:59 p.m. ET |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| | | **While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.** | | |
| **Innovation in Care and Support Award**<br>**Go to:**<br>• Program Announcement<br>• General Application Instructions<br>**Grants.gov Funding Opportunity Number:**<br>W81XWH-20-PRARP-InCASA | **Level I:** Investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but **below** the level of Assistant Professor (or equivalent) at the time of the application submission deadline.<br>• Mentor required.<br><br>**Level II:** The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). | **Intent:** To support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with the common symptoms of TBI and/or AD/ADRD.<br>• **Level I**: Applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the Mentor(s). The Mentor(s) must possess qualifications, background, and experience in TBI and/or AD/ADRD research.<br>• **Level II** is intended to support PIs from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline.<br><br>**Applications must address one of the following FY20 PRARP Overarching Challenges:**<br>• Paucity of Clinical Studies<br>• Quality of Life<br>• Family and Care Support<br><br>**Applications should address one of the following FY20 PRARP Focus Areas:**<br>• Biomarkers<br>• Quality of Life<br>• Family and Caregiver Support<br>• Nonpharmacological Interventions and Devices<br>• Bioinformatics<br><br>**Applications are limited to the choice of one dementia category for the overall application:**<br>• Cognitive Symptomatology | **Level I**:<br>• Maximum funding of **$225,000** for direct costs (plus indirect costs).<br>• Maximum period of performance is **3** years.<br><br>**Level II**:<br>• Maximum funding of **$500,000** for direct costs (plus indirect costs).<br>• Maximum period of performance is **3** years.<br><br>**For Both Levels:**<br>Indirect costs may be proposed in accordance with the institution's rate agreement. | **Pre-Application (Letter of Intent):**<br>June 22, 2020, 5:00 p.m. ET<br><br>**Application:**<br>July 21, 2020, 11:59 p.m. ET |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| | | • Behavioral/Mood Symptomatology (e.g., Stress, Anxiety, Depression, Disinhibition, Aggression, and Poor Judgement)<br>• Social Isolation<br>• Autonomy and Activities of Daily Living<br>• Sleep Challenges and Disorders<br>**Pharmacological interventions are specifically discouraged.**<br>**Animal research is prohibited.**<br>**While not required, applications to either Funding Level I or II are encouraged to provide relevant preliminary data.** | | |
| **Research Partnership Award**<br>**Go to:**<br>• Program Announcement<br>• General Application Instructions<br>**Grants.gov Funding Opportunity Number:**<br>W81XWH-20-PRARP-RPA | The initiating PI must be an independent investigator **at or above** the level of Assistant Professor (or equivalent).<br>Each named Co-PI must be **at or above** the level of assistant professor (or equivalent). | **Intent:** To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.<br>**Applications must include clearly stated plans for interactions between/among the partners. The plans must include communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among all investigators and organizations participating in the project.**<br>**Applications must address one of the following FY20 PRARP Overarching Challenges:**<br>• Foundational Research<br>• Paucity of Clinical Studies<br>• Diagnostics and Prognostics<br>• Epidemiology<br>• Quality of Life<br>• Family and Care Support | • Funding limit is **$1.3 million (M)** in total costs.<br>• Maximum period of performance is **3** years.<br>• Indirect costs may be proposed in accordance with the institution's rate agreement. | **Pre-Application (Letter of Intent):**<br>June 22, 2020, 5:00 p.m. ET<br>**Application:**<br>July 21, 2020, 11:59 p.m. ET |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| | | **Applications should address at least one of the following FY20 PRARP Focus Areas:**<br>• Mechanisms of Pathogenesis<br>• Biomarkers<br>• Quality of Life<br>• Family and Caregiver Support<br>• Epidemiology<br>• Novel Target Identification<br>• Nonpharmacological Interventions and Devices<br>• Bioinformatics<br>**Applications selecting either the "Quality of Life" or "Family and Care Support" Overarching Challenge are limited to the choice of one the following symptomatology categories for the overall application:**<br>• Cognitive Symptomatology<br>• Behavioral/Mood Symptomatology (e.g., Stress, Anxiety, Depression, Disinhibition, Aggression, and Poor Judgement)<br>• Social Isolation<br>• Autonomy and Activities of Daily Living<br>• Sleep Challenges and Disorders<br>**Pharmacological interventions are specifically discouraged.**<br>**Preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are *required*.** | | |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| **Accelerating Diagnostics for Traumatic Brain Injury Research Award**<br>**Go to:**<br>• Program Announcement<br>• General Application Instructions<br>**Grants.gov Funding Opportunity Number:**<br>W81XWH-20-PRARP-ADTBI | The PI must be an independent investigator **at or above** the level of Assistant Professor (or equivalent). | **Intent:** To support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for chronic TBI as they pertain to AD/ADRD.<br>**Applications must address the "Diagnostics and Prognostics" Overarching Challenge and the "Biomarkers" Focus Area.**<br>**Applications are limited to the choice of one of the following biomarker categories for the overall application:**<br>• Fluid-Based Biomarkers<br>• Imaging-Based Biomarkers<br>• Retinal Biomarkers<br>• Wearable Devices<br>• Other<br>**Pharmacological interventions are specifically discouraged.**<br>**Animal research is explicitly discouraged.**<br>**Preliminary data regarding the suitability of the biomarker(s) for further testing toward biomarker qualification is *required*.** | • Funding limit is **$2.8M** in total costs.<br>• Maximum period of performance is **4** years.<br>• Indirect costs may be proposed in accordance with the institution's rate agreement. | **Pre-Application (Letter of Intent):**<br>June 22, 2020, 5:00 p.m. ET<br>**Application:**<br>July 21, 2020, 11:59 p.m. ET |
| **Leveraging Approaches for Innovation in Care and Support Award**<br>**Go to:**<br>• Program Announcement<br>• General Application Instructions<br>**Grants.gov Funding Opportunity Number:** | The Coordinating Center PI must be **at or above** the level of assistant professor (or equivalent).<br>Each named Partnering Site PI must be **at or above** the level of an assistant professor (or equivalent. | **Intent:** To support multi-institutional, harmonized, innovative and impactful research initiatives that improves the quality of life and care for individuals, families, and care providers living with the common symptoms of TBI and/or AD/ADRD.<br>**Applications must address one of the following FY20 PRARP Overarching Challenges:**<br>• Quality of Life<br>• Family and Care Support | • Funding limit is **$2.8M** in total costs.<br>• Maximum period of performance is **4** years.<br>Indirect costs may be proposed in accordance with the institution's rate agreement. | **Pre-Application (Letter of Intent):**<br>June 22, 2020, 5:00 p.m. ET<br>**Application:**<br>July 21, 2020, 11:59 p.m. ET |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| W81XWH-20-PRARP-LEAP-InCASA | | **Applications should address one of the following FY20 PRARP Focus Areas:**<br>• Biomarkers<br>• Quality of Life<br>• Family and Caregiver Support<br>• Nonpharmacological Interventions and Devices<br>• Bioinformatics<br>**Applications are limited to the choice of one of the following symptomatology categories for the overall application:**<br>• Cognitive Symptomatology<br>• Behavioral/Mood Symptomatology (e.g., Stress, Anxiety, Depression, Disinhibition, Aggression, and Poor Judgement)<br>• Social Isolation<br>• Autonomy and Activities of Daily Living<br>• Sleep Challenges and Disorders<br>**Requires a Coordinating Center and at least two Partnering Sites.**<br>• The Coordinating Center provides overall leadership and management infrastructure for all research initiatives.<br>• Each Partnering Site should develop its own unique research initiative as relevant to the overall application design.<br>• The Coordinating Center participates as a separate study arm for each Partnering Site's study.<br>• Coordinating and Partnering Sites work together to harmonize research protocols, participant accrual strategies, and analyze data. | | |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| | | • Plans for interactions between/among the partners should be well detailed and must include communication, decision-making, allocation of resources, and coordination of research progress and results among all Partnering Sites.<br>• Each Partnering Site should detail a research initiative that is unique from the other Partnering Sites.<br>**The Coordinating Center applicant organization will submit and the individual named as the PI in the application will be designated as the PI; the other partner(s) will be designated as the Co-PI(s).**<br>**The Coordinating Center must be from a different institution than the Partnering Sites.**<br>**The Partnering Sites Applicant Organizations must be from different institutions.**<br>**Pharmacological interventions are specifically discouraged.**<br>**Animal research is prohibited.**<br>**Preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are *required*.** | | |